Repare Therapeutics (RPTX) Competitors $1.47 +0.02 (+1.17%) Closing price 03:59 PM EasternExtended Trading$1.44 -0.03 (-1.77%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RPTX vs. ANNX, FHTX, SLRN, DSGN, URGN, CRDF, CGC, PROK, GNFT, and DBVTShould you be buying Repare Therapeutics stock or one of its competitors? The main competitors of Repare Therapeutics include Annexon (ANNX), Foghorn Therapeutics (FHTX), Acelyrin (SLRN), Design Therapeutics (DSGN), UroGen Pharma (URGN), Cardiff Oncology (CRDF), Canopy Growth (CGC), ProKidney (PROK), Genfit (GNFT), and DBV Technologies (DBVT). These companies are all part of the "pharmaceutical products" industry. Repare Therapeutics vs. Its Competitors Annexon Foghorn Therapeutics Acelyrin Design Therapeutics UroGen Pharma Cardiff Oncology Canopy Growth ProKidney Genfit DBV Technologies Repare Therapeutics (NASDAQ:RPTX) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership, media sentiment and community ranking. Does the media refer more to RPTX or ANNX? In the previous week, Annexon had 4 more articles in the media than Repare Therapeutics. MarketBeat recorded 6 mentions for Annexon and 2 mentions for Repare Therapeutics. Annexon's average media sentiment score of 1.14 beat Repare Therapeutics' score of 0.93 indicating that Annexon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repare Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annexon 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, RPTX or ANNX? Repare Therapeutics has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Annexon has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Do analysts rate RPTX or ANNX? Repare Therapeutics presently has a consensus price target of $4.50, indicating a potential upside of 206.75%. Annexon has a consensus price target of $12.50, indicating a potential upside of 402.01%. Given Annexon's stronger consensus rating and higher probable upside, analysts clearly believe Annexon is more favorable than Repare Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Repare Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Annexon 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation and earnings, RPTX or ANNX? Repare Therapeutics has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Repare Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRepare Therapeutics$1.07M58.64-$93.80M-$3.01-0.49AnnexonN/AN/A-$134.24M-$1.18-2.11 Does the MarketBeat Community believe in RPTX or ANNX? Annexon received 14 more outperform votes than Repare Therapeutics when rated by MarketBeat users. Likewise, 78.08% of users gave Annexon an outperform vote while only 64.18% of users gave Repare Therapeutics an outperform vote. CompanyUnderperformOutperformRepare TherapeuticsOutperform Votes4364.18% Underperform Votes2435.82% AnnexonOutperform Votes5778.08% Underperform Votes1621.92% Is RPTX or ANNX more profitable? Annexon has a net margin of 0.00% compared to Repare Therapeutics' net margin of -99.76%. Annexon's return on equity of -38.99% beat Repare Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Repare Therapeutics-99.76% -40.87% -35.07% Annexon N/A -38.99%-33.90% Do institutionals and insiders hold more shares of RPTX or ANNX? 85.1% of Repare Therapeutics shares are held by institutional investors. 11.5% of Repare Therapeutics shares are held by company insiders. Comparatively, 11.9% of Annexon shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryAnnexon beats Repare Therapeutics on 13 of the 17 factors compared between the two stocks. Get Repare Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RPTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RPTX vs. The Competition Export to ExcelMetricRepare TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.92M$6.88B$5.58B$8.50BDividend YieldN/A2.53%5.28%4.17%P/E Ratio-0.738.5527.1919.64Price / Sales58.64262.61408.78152.17Price / CashN/A65.8538.3234.64Price / Book0.296.536.974.60Net Income-$93.80M$143.48M$3.23B$248.06M7 Day Performance-0.20%0.20%-0.88%-1.02%1 Month Performance2.59%10.93%7.81%3.51%1 Year Performance-62.58%2.46%31.53%12.68% Repare Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RPTXRepare Therapeutics2.428 of 5 stars$1.47+1.2%$4.50+206.7%-63.7%$62.92M$1.07M-0.73180ANNXAnnexon2.3942 of 5 stars$2.12+3.9%$12.50+489.6%-55.1%$232.59MN/A-2.0260Positive NewsAnalyst RevisionGap DownFHTXFoghorn Therapeutics2.1687 of 5 stars$4.17+2.2%$12.13+190.8%-24.7%$232.44M$23.50M-2.17120SLRNAcelyrin3.3946 of 5 stars$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135DSGNDesign Therapeutics0.6499 of 5 stars$4.02+7.8%$4.00-0.5%+3.7%$228.21MN/A-4.7340Positive NewsGap UpURGNUroGen Pharma4.6159 of 5 stars$4.84+14.2%$27.43+466.7%-12.9%$223.16M$91.87M-1.54200Trending NewsAnalyst ForecastShort Interest ↓Gap UpHigh Trading VolumeCRDFCardiff Oncology1.8155 of 5 stars$3.35-1.8%$12.00+258.2%+28.5%$222.86M$587K-3.5620Gap UpCGCCanopy Growth2.5432 of 5 stars$1.21-8.3%$2.00+65.3%-79.8%$222.48M$276.75M-0.323,150Positive NewsHigh Trading VolumePROKProKidney2.4352 of 5 stars$0.75+3.2%$5.00+570.3%-70.0%$218.32M$306K-1.363Positive NewsGNFTGenfit2.5587 of 5 stars$4.34-3.8%$13.00+199.7%-14.3%$216.83M$67.00M0.00120Positive NewsShort Interest ↓Gap UpDBVTDBV Technologies3.4018 of 5 stars$7.74-7.3%$14.75+90.6%+84.6%$212.00M$15.73M-1.7280Positive News Related Companies and Tools Related Companies Annexon Alternatives Foghorn Therapeutics Alternatives Acelyrin Alternatives Design Therapeutics Alternatives UroGen Pharma Alternatives Cardiff Oncology Alternatives Canopy Growth Alternatives ProKidney Alternatives Genfit Alternatives DBV Technologies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RPTX) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repare Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repare Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RPTX Stock Free RPTX Stock Alerts